# Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

> **NCT00660920** · PHASE1 · COMPLETED · sponsor: **Ariad Pharmaceuticals** · enrollment: 81 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia
- Hematologic Malignancies

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT00660920
- **Lead sponsor:** Ariad Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2018-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660920, "Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00660920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*